. 2013 Jan 31;2013(1):CD007633. doi: 10.1002/14651858.CD007633.pub2

6. Mean improvement of nail features ≥ 50%.

Study	Intervention and control group	Features not specified	Pitting	Leukonychia	Red spots lunula	Crumbling	Onycholysis	Splinter haemorrhages	Oil drop discolourations	Subungual hyperkeratosis
Short‐term treatment
Cannavo	I: Topical ciclosporin 70% in maize oil (median) C: Maisoil	‐	100%^nsb no data	‐	‐	100%^sb no data	100%^sb no data	‐	75%^nsb no data	83%^sb no data
De Jong	I: 1% 5‐fluorouracil in Belanyx® lotion C: Belanyx® lotion	‐	‐	‐	‐	‐	‐	‐	63%^{ns, sb} 57%^{ns, sb}	‐
Igarashi	I: Ustekinumab 45 or 90 mg C: Placebo	# #	‐	‐	‐	‐	‐	‐	‐	‐
Kwang	I: Electron beam 0.75 Gy C: Placebo	‐	‐	‐	‐	‐	‐	‐	‐	X X
Levell	I: Systemic ciclosporin 2.5 mg/kg C: Topical dithranol 2% to 8% + 0.5% salicylic acid + UVB	# #	‐	‐	‐	‐	‐	‐	‐	‐
Lindelof	I: Grenz rays 5Gy C: Placebo	# #	‐	‐	‐	‐	‐	‐	‐	‐
Mahrle	I: Systemic ciclosporin 2.5 mg/kg C: Etretinate	# #	‐	‐	‐	‐	‐	‐	‐	‐
Rigopoulos	I: Tazarotene 0.1% cream C: Clobetasol propionate 0.05%	‐	75%^ns,sb 67%^ns,sb	‐	‐	‐	58%^{ns, sb} 57%^{ns, sb}	‐	85%^{ns, sb} 82%^{ns, sb}	80%^{ns, sb} 66%^{ns, sb}
Tosti	I: Calcipotriol C: Betamethason dipropionate 64 mg/g + salicylic acid 0.03 g/g	‐	‐	‐	‐	‐	‐	‐	‐	< 50%^ns* < 50%^ns*
Tzung	I: Calcipotriol 0.005% C: Calcipotriol 0.005% + betamethasone dipropionate 0.05%	‐	‐	‐	‐	‐	‐	‐	X^s X^s	‐
Yu	I: Superficial radiotherapy 450 cGy C: 'Sham radiotherapy'	# #	‐	‐	‐	‐	‐	‐	‐	‐
Medium and long‐term treatment
Baran 1999	I: Topical 8% clobetasol C: Placebo lacquer	‐	‐	‐	‐	‐	X no data	‐	‐	‐
Baran 1999a	I: Topical 8% clobetasol C: Placebo lacquer	‐	‐	‐	‐	‐	X no data	‐	‐	‐
Flori	I: Hyaluronic acid + chondroitin sulphates C: Placebo	‐	‐	‐	‐	‐	68.8% ^{s, sb} < 50%^sb**	‐	‐	70%^{s, sb} < 50%^sb**
Gűműşel	I: Methotrexate 15 mg C: Ciclosporin 5 mg/kg	# #	‐	‐	‐	‐	‐	‐	‐	‐
Igarashi	I: Ustekinumab 45 or 90 mg C: Placebo	# #	‐	‐	‐	‐	‐	‐	‐	‐
Kavanaugh	I: Golimumab 50 or 100 mg C: Placebo	# #	‐	‐	‐	‐	‐	‐	‐	‐
Rich^{*** (% participants with complete clearance)}	I: Infliximab 5 mg/kg C: Placebo/ infliximab	‐	56%^s 68%^s	82%^s 82%^s	96%^s 100%^s	67%^s 76%^s	73%^s 78%^s	88%^s 90%^s	81%^s 86%^s	79%^s 84%^s
Scher	I: Tazarotene gel 0.1% C: Vehicle gel	‐	X^s no data	‐	‐	‐	X^s no data	‐	‐	‐

This table contains the eight nail features used in the NAPSI score. The percentages are score improvements compared to baseline at the end of treatment duration. Comparison between studies is difficult, because not all studies assessed all eight features of the NAPSI. It is unclear if this is an improvement of more or less than 50%.

I = intervention   C = control   S = significant between the two treatment groups   ns = not significant between the two treatment groups   sb = significant to baseline   nsb = not significant to baseline   # = nail feature was not specified in the trial   X = most improved nail feature in this study, but unknown percentage

*: After 3 months, there was a response of 26.5%^ns in the calcipotriol group vs 30.4%^ns in the betamethasone group.   **: After 90 days, there was a response of 35.5%^sb for onycholysis and 23.8%^sb for hyperkeratosis.

*** Rich reported percentage of participants with complete clearance at week 50, not a percentage of score improvement. We have no data about the improvement of the remaining percentage of participants.